FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018677912> ?p ?o ?g. }

• W2018677912 endingPage "8" @default.
• W2018677912 startingPage "451" @default.
• W2018677912 abstract "Visfatin is a newly identified adipocytokine that mimics insulin action. However, the pathophysiological role of visfatin in diabetic patients is not fully understood. The main purpose of this study was to investigate the association of plasma visfatin with endothelial function in patients with type 2 diabetes mellitus. In addition, the relationships of visfatin with oxidative stress, low-grade inflammation, atherosclerosis, adiponectin, plasma renin activity, and aldosterone were also explored, and the effect of pioglitazone on visfatin was examined. Visfatin levels were measured in 80 patients with type 2 diabetes mellitus and in 28 age-matched healthy subjects. Endothelial function was evaluated by using flow-mediated vasodilatation (FMD), oxidative stress was assessed by the level of urinary 8-iso-prostaglandin F2alpha, and atherosclerosis and inflammation were measured by using the intimal-medial complex thickness and the levels of high-sensitivity C-reactive protein and fibrinogen. Pioglitazone was administered for 12 weeks at a dose of 30 mg/d in a further 20 patients with type 2 diabetes mellitus. There was a significant negative correlation between the log10-transformed (log) plasma visfatin concentration and FMD or creatinine clearance (R=-0.2672, P=.0167; R=-0.2750, P=.0136). Log visfatin was also positively correlated with log urinary albumin excretion (R=0.2305, P=.0397). In addition, it was also found that visfatin had a significant negative correlation with plasma aldosterone (R=-0.2432, P=.0297). In stepwise regression analysis, creatinine clearance, log aldosterone, FMD, and sex showed a significant association with log visfatin (P=.0040, P=.0069, P=.0444, and P=.0487, respectively), and log 8-iso-prostaglandin F2alpha showed a tendency for an association (P=.0515). Pioglitazone therapy did not affect the visfatin concentration in the 20 pioglitazone-treated patients with diabetes, although a significant elevation of visfatin was obtained in a subgroup of 11 female patients (P=.0381). In conclusion, the current study showed that visfatin is negatively associated with vascular endothelial function evaluated by FMD and creatinine clearance, and positively associated with log urinary albumin excretion. Visfatin was also negatively correlated with circulating aldosterone. Pioglitazone therapy for 12 weeks did not affect the plasma visfatin concentration significantly in all diabetic patients, but a significant elevation in visfatin was obtained in women only." @default.
• W2018677912 created "2016-06-24" @default.
• W2018677912 creator A5002804119 @default.
• W2018677912 creator A5009998678 @default.
• W2018677912 creator A5027027003 @default.
• W2018677912 creator A5059661674 @default.
• W2018677912 creator A5063357446 @default.
• W2018677912 date "2007-04-01" @default.
• W2018677912 modified "2023-10-18" @default.
• W2018677912 title "Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus." @default.
• W2018677912 cites W1555489744 @default.
• W2018677912 cites W1965148671 @default.
• W2018677912 cites W1965393911 @default.
• W2018677912 cites W1989200821 @default.
• W2018677912 cites W2000097848 @default.
• W2018677912 cites W2008288517 @default.
• W2018677912 cites W2014663082 @default.
• W2018677912 cites W2015279471 @default.
• W2018677912 cites W2016521230 @default.
• W2018677912 cites W2017499355 @default.
• W2018677912 cites W2020949125 @default.
• W2018677912 cites W2042706232 @default.
• W2018677912 cites W2051625732 @default.
• W2018677912 cites W2052441984 @default.
• W2018677912 cites W2057180728 @default.
• W2018677912 cites W2069240139 @default.
• W2018677912 cites W2078412974 @default.
• W2018677912 cites W2079115802 @default.
• W2018677912 cites W2087724955 @default.
• W2018677912 cites W2090289803 @default.
• W2018677912 cites W2090439216 @default.
• W2018677912 cites W2123258346 @default.
• W2018677912 cites W2123706364 @default.
• W2018677912 cites W2124821727 @default.
• W2018677912 cites W2135110328 @default.
• W2018677912 cites W2139801418 @default.
• W2018677912 cites W2141608973 @default.
• W2018677912 cites W2141998216 @default.
• W2018677912 cites W2153366902 @default.
• W2018677912 cites W2155867477 @default.
• W2018677912 cites W2156783035 @default.
• W2018677912 cites W2165047605 @default.
• W2018677912 cites W2166751358 @default.
• W2018677912 cites W2238050922 @default.
• W2018677912 cites W4235391466 @default.
• W2018677912 doi "https://doi.org/10.1016/j.metabol.2006.12.001" @default.
• W2018677912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17378999" @default.
• W2018677912 hasPublicationYear "2007" @default.
• W2018677912 type Work @default.
• W2018677912 sameAs 2018677912 @default.
• W2018677912 citedByCount "158" @default.
• W2018677912 countsByYear W20186779122012 @default.
• W2018677912 countsByYear W20186779122013 @default.
• W2018677912 countsByYear W20186779122014 @default.
• W2018677912 countsByYear W20186779122015 @default.
• W2018677912 countsByYear W20186779122016 @default.
• W2018677912 countsByYear W20186779122017 @default.
• W2018677912 countsByYear W20186779122018 @default.
• W2018677912 countsByYear W20186779122019 @default.
• W2018677912 countsByYear W20186779122020 @default.
• W2018677912 countsByYear W20186779122021 @default.
• W2018677912 countsByYear W20186779122022 @default.
• W2018677912 countsByYear W20186779122023 @default.
• W2018677912 crossrefType "journal-article" @default.
• W2018677912 hasAuthorship W2018677912A5002804119 @default.
• W2018677912 hasAuthorship W2018677912A5009998678 @default.
• W2018677912 hasAuthorship W2018677912A5027027003 @default.
• W2018677912 hasAuthorship W2018677912A5059661674 @default.
• W2018677912 hasAuthorship W2018677912A5063357446 @default.
• W2018677912 hasConcept C126322002 @default.
• W2018677912 hasConcept C134018914 @default.
• W2018677912 hasConcept C159641895 @default.
• W2018677912 hasConcept C194832188 @default.
• W2018677912 hasConcept C2776151105 @default.
• W2018677912 hasConcept C2776782570 @default.
• W2018677912 hasConcept C2777180221 @default.
• W2018677912 hasConcept C2777391703 @default.
• W2018677912 hasConcept C2778525890 @default.
• W2018677912 hasConcept C2780306776 @default.
• W2018677912 hasConcept C2780972559 @default.
• W2018677912 hasConcept C2910068830 @default.
• W2018677912 hasConcept C555293320 @default.
• W2018677912 hasConcept C71924100 @default.
• W2018677912 hasConceptScore W2018677912C126322002 @default.
• W2018677912 hasConceptScore W2018677912C134018914 @default.
• W2018677912 hasConceptScore W2018677912C159641895 @default.
• W2018677912 hasConceptScore W2018677912C194832188 @default.
• W2018677912 hasConceptScore W2018677912C2776151105 @default.
• W2018677912 hasConceptScore W2018677912C2776782570 @default.
• W2018677912 hasConceptScore W2018677912C2777180221 @default.
• W2018677912 hasConceptScore W2018677912C2777391703 @default.
• W2018677912 hasConceptScore W2018677912C2778525890 @default.
• W2018677912 hasConceptScore W2018677912C2780306776 @default.
• W2018677912 hasConceptScore W2018677912C2780972559 @default.
• W2018677912 hasConceptScore W2018677912C2910068830 @default.
• W2018677912 hasConceptScore W2018677912C555293320 @default.
• W2018677912 hasConceptScore W2018677912C71924100 @default.
• W2018677912 hasIssue "4" @default.

• next